HopeStage
Back to all studies
TerminatedNCT04613453

Reducing Adolescent Suicide prevention: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

Medication studyAges 13–17United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 13 years to 17 years.

Listed locations
New HavenSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 21, 2022
Recruitment status
Terminated
Enrollment listed in the registry
12
Sponsor
Yale University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 13 Years to 17 Years
Official registry ID
NCT04613453
Official title
Show the full official title

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

Recruitment & locations

Terminated

New Haven

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Yale University, a university.

Does this study involve medication?

Yes. The study involves medication, including Ketamine Infusion and Midazolam Infusion.

Who can participate?

Listed age limits: 13 years to 17 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies